HQH News and Press, Tekla Healthcare Investors From 05/19/21

Tekla Healthcare Investors (HQH) declares $0.50/share quarterly dividend, -2% decrease from prior dividend of $0.51.Forward yield 8.38%Payable June 30; for shareholders of record May 28; ex-div May 27.See HQH Dividend Scorecard, Yield Chart, & Dividend Growth. For further details see: ...

Healthcare offers essential services that people can't go without, recession or not. The Tekla funds can offer potential in any one of their funds for healthcare exposure. Today we explore the differences and the similarities of the funds. For further details see: Tekla ...

Opportunities and risks in the healthcare sector. The next big areas of innovation in healthcare. Extreme winners and losers in the healthcare sector. For further details see: Building A Healthy Portfolio: Spotlight On Healthcare

In January 2020, only 0.24% of total medical claims in the U.S. were telemedicine-related. One year later, they totaled 7%. It took 15 years for e-commerce penetration to rise from less than 1% to over 7%. The pandemic helped telemedicine do it in one. Population-wide immunity to ...

Current economic data is certainly strong - although not universally so - but the bond and currency markets may be pointing to some weakness ahead. The copper to gold ratio which peaked in early March, leading bond yields by a full month, has recently resumed its uptrend. The comm...

Since U.S. Treasury bonds have fallen more than -20% in value, it looks like we might've seen a short-term bottom and an opportunity to profit in the bond market. Which sectors are performing well in the intermediate term, as well as those that are taking a breather in the short term....

If you've just retired and had a sizable chunk of cash to put to work, where can you earn a decent income while preserving and growing your capital? You may be in a situation where you need to move away from a fund-based investment approach to a self-managed income-oriented stock inve...

The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively resilient throughout the pandemic, we expect a full recovery in the latter half of thi...

Some in the investment community are spooked by the upcoming loss of Humira exclusivity. Revenue will likely fall in 2023, but the acquisition of Allergan, as well as the growth of revenue from Rinvoq, Skyrizi and Imbruvica should fill the gap. Management guides for high single-di...

I reveal two areas that I have invested half of my retirement funds into. I expect my hard-earned money to work as hard as I do, earning me more money. The main focus remains on high yield and recurrent income so I can enjoy my retirement. However, my new investment strategy t...